Qilian International Holding Group Limited (BGM) AI Stock Analysis
BGM AI stock analysis summary
AI ResearchQilian International Holding Group Limited (BGM) is a China-based pharmaceutical and chemical company producing oxytetracycline, licorice, heparin, and allied products. In FY2025, revenue rose 51.1% to $37.9M, while net income stood at -$19.9M with an operating margin of -33.2%. As of March 31, 2026, the company held $11.5M in cash and short-term investments with a net cash position of $10.4M.
- Market cap
- $115.5M
- Revenue (TTM)
- $47.9M
- P/E
- —
- 1Y return
- -96.9% S&P 500 16.8%
- Avg. target
- —
Bull case
- Quarterly revenue grew 69.8% year-over-year in the period ended March 31, 2026, supporting trailing twelve-month revenue of $47.9M.
- The balance sheet maintains low leverage with a debt-to-equity ratio of 0.00 and net cash of $10.4M as of March 31, 2026.
- Shares trade at a price-to-book ratio of 0.3x and a price-to-sales multiple of 2.4x, below the 4.1x median for US-listed Healthcare peers.
Bear case
- The company reported annual net income of -$19.9M in FY2025 alongside operating cash flow of -$2.4M.
- BGM shares have fallen 96.9% over the past 1-year period, underperforming the 16.8% gain for the S&P 500.
- Free cash flow has remained negative in four of the last five reported fiscal years, including -$4.4M in FY2025.
What Qilian International does
Qilian International Holding Group Limited, also operating as BGM Group Ltd., is a China-based pharmaceutical and chemical company. The firm operates across three segments: Diversified Pharmaceutical and Allied Products, AI Solution, and Insurance Business. Its product lines include oxytetracycline products such as Qilian Shan tablets and active pharmaceutical ingredients, as well as Gan Di Xin and Qilian Shan licorice extracts. In addition, the company produces Ahan antibacterial paste, heparin sodium preparations for cardiovascular and cerebrovascular conditions, Zhu Xiaochang sausage casings for culinary applications, and Xiongguan organic fertilizers designed to improve crop yield.
Growth and profitability
Revenue contracted at a 5-year CAGR of -5.4% from FY2020 to FY2025. After reaching $64.9M in FY2022 with net income of $1.1M, revenue fell 28.3% to $46.5M in FY2023 and declined 46.0% to $25.1M in FY2024. In FY2025, revenue rose 51.1% to $37.9M, though operating margin stood at -33.2% and net income was -$19.9M. For the trailing twelve months ended March 31, 2026, revenue totaled $47.9M with a profit margin of -44.2% and EPS of -$4.80. In the latest quarter ended March 31, 2026, quarterly revenue grew 69.8% year-over-year.
Balance sheet and cash flow
As of March 31, 2026, the company held $11.5M in cash and short-term investments alongside total debt of $1.2M, yielding net cash of $10.4M. Shareholders' equity was $398.2M, with a current ratio of 1.25 and a debt-to-equity ratio of 0.00. For FY2025, operating cash flow was -$2.4M and free cash flow was -$4.4M, with capital expenditures of $2.1M. Over the past five years, the company reduced its share count by 11.6%.
Valuation and performance
BGM trades at a price-to-sales multiple of 2.4x and an enterprise value to revenue multiple of 1.9x, both below the median price-to-sales multiple of 4.1x for its 1056 US-listed Healthcare peers. Its price-to-book ratio is 0.3x. At a market capitalization of $115.5M and an enterprise value of $91.7M, the stock closed at $8.65 on October 16, 2026, which is 64.5% below its 200-day moving average. Over the trailing 1-year period, the stock fell 96.9%, compared to a 16.8% return for the S&P 500 (SPY).
What analysts expect
Quotelinks research tracks public market earnings performance for Qilian International Holding Group Limited. Over the trailing four quarters reported, the company beat consensus earnings per share estimates 2 times. Analyst coverage details such as formal rating distributions, consensus price targets, earnings projections, and scheduled upcoming earnings release dates are not available for this issuer. The stock last closed at $8.65 on October 16, 2026, compared to a 52-week trading range of $6.45 to $303.00.
Key risks and what to watch
- Ongoing operational losses are reflected in a trailing twelve-month profit margin of -44.2% and EPS of -$4.80.
- Operating margin deteriorated from 4.2% in FY2021 to -33.2% in FY2025, demonstrating sustained operating deficits.
- The stock exhibits high price volatility, indicated by a beta of 1.46 and a 52-week range spanning from $6.45 to $303.00.
- Cash reserves of $11.5M as of March 31, 2026 could be pressured if annual free cash flow deficits persist near the -$4.4M recorded in FY2025.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BGM AI stock analysis
This page is an AI-written research summary of Qilian International Holding Group Limited (BGM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BGM income statement, BGM balance sheet, BGM key metrics, BGM chart. See the BGM stock overview for the latest quote and news.
BGM AI stock analysis FAQ
What does Qilian International Holding Group Limited do?
Qilian International Holding Group Limited operates as a pharmaceutical and chemical company in China across segments including Diversified Pharmaceutical and Allied Products, AI Solution, and Insurance Business. Its products include oxytetracycline preparations, licorice extracts, heparin sodium preparations, traditional Chinese medicines, organic fertilizers, and culinary sausage casings.
What are BGM's recent revenue and earnings figures?
For the trailing twelve months ended March 31, 2026, BGM generated $47.9M in revenue with a profit margin of -44.2% and an EPS of -$4.80. In FY2025, annual revenue reached $37.9M, accompanied by net income of -$19.9M.
What is BGM's cash and debt position?
As of March 31, 2026, BGM held $11.5M in cash and short-term investments against $1.2M in total debt, resulting in net cash of $10.4M. Shareholders' equity was $398.2M, with a debt-to-equity ratio of 0.00.
Does BGM pay a dividend?
BGM does not report regular dividend payments. In FY2025, corporate cash deployment included $2.1M in capital expenditures.
How has BGM stock performed relative to the market?
BGM closed at $8.65 on October 16, 2026, down 92.2% year-to-date and 96.9% over the trailing 1-year period. In comparison, the S&P 500 (SPY) returned 16.8% over the same 1-year timeframe.